Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b studies being conducted in South Africa.

The UK phase III clinical trial involves more than 15,000 participants aged 18-84 years. During a period of high transmission with the UK variant of SARS-CoV-2, the preliminary results show an efficacy rate of 89.3%. After review of the vaccine safety database it has also been reported that any adverse events were balanced between both the vaccine and the placebo groups and any serious or severe side effects occurred at low levels.

In the South African phase 2b clinical trial, an efficacy rate of 60% was seen in the HIV-negative cohort, with an overall 49.4% efficacy rate seen across the total 4,400 trial participants (both HIV-negative and HIV positive individuals). During the time of the trial, the South African variant of SARS-CoV-2 was widely circulating.

The Novavax COVID-19 vaccine candidate is a protein-based vaccine utilising a nanoparticle technology platform.

To read the full press release follow the link below:

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial